| 恩格列净与DDP4抑制剂治疗2型糖尿病疗效比较的Meta分析 |
| 投稿时间：2016-08-05 修订日期：2016-08-05 点此下载全文 |
| 引用本文：杨哲普,毕会民.恩格列净与DDP4抑制剂治疗2型糖尿病疗效比较的Meta分析[J].医学研究杂志,2017,46(4):116-123 |
| DOI：
10.11969/j.issn.1673-548X.2017.04.031 |
| 摘要点击次数: 1065 |
| 全文下载次数: 781 |
|
|
| 中文摘要:目的 系统性评价恩格列净与DDP4抑制剂治疗2型糖尿病疗效比较。方法 计算机检索PubMed、Embase、Cochrane图书馆、the ISI Web of Knowledge Databases、VIP、CNKI、CBM和万方数据库，查找所有比较恩格列净和DDP4抑制剂2型糖尿病的随机对照试验（RCT），检索时限均为建库至2016年3月28日。同时手检纳入文献的参考文献，按纳入排除标准由2人独立进行RCT的筛选、资料提取和质量评价后，采用RevMan 5.1软件进行Meta分析，并采用Cochrane系统评价的办法评价纳入研究质量。结果 纳入符合标准的随机对照试验5例，共计患者1935例。Meta分析结果显示，在有效性方面：与DDP4抑制剂（利拉西汀、西格列汀）相比，两组降低糖化血红蛋白相似（MD=-0.07，95%CI：-0.13~-0.01，P < 0.05）、恩格列净组空腹血糖明显降低（MD=-16.73，95%CI：-21.02~-12.43，P < 0.01）、体重减轻（MD=-2.43，95%CI：-2.68~-2.19，P < 0.01）。在安全性方面，两组间低血糖发生率相似，差异无统计学意义（OR=0.86，95%CI：0.46~1.6，P > 0.05）、恩格列净组生殖系统感染发生率明显增高，差异有统计学意义（OR=2.85，95%CI：1.71~4.76，P < 0.01）。结论 恩格列净组与DDP4抑制剂组相比，能够明显降低空腹血糖、体重，但生殖系统感染率增高。 |
| 中文关键词:恩格列净 DDP4抑制剂 2型糖尿病 Meta分析 |
| |
| SGLT2 versus DPP4 Inhibitors for Type 2 Diabetes:A Meta-analysis |
|
|
| Abstract:Objective To compare the efficacy of empagliflozin and DDP4 inhibitors in the treatment of type 2 diabetes mellitus. Methods With Computer,we retrieval PubMed, Cochrane Library, EMbase, CNKI,CBM and Wanfang database to find all of the randomized controlled trials about the effectiveness and safety of empagliflozin and DDP4 inhibitors in the treatment of type 2 diabetes mellitus. The retrieval time was from the establishment of database to March,2016.References screen were performed manually. Meta-analysis was carried out using RevMan 5.2 software. Results A total of five studies included 1935 cases. The Meta analysis results showed that: HbA1c level (MD=-0.07, 95%CI :-0.13--0.01, P < 0.05),fasting blood glucose (MD=-16.73, 95%CI:-21.02--12.43, P < 0.01), weight loss level (MD=-2.43 95%CI:-2.68--2.19,P < 0.01) in the two groups showed statistically significant differences. Empagliflozin group was better than DDP4 inhibitors group in reducing HbA1c level, fasting blood glucose, weight loss level. Safety: hypoglycemia between the two groups were similar (OR=0.86, 95%CI :0.46-1.6, P > 0.05). Empagliflozin group's genital tract infection rate was statistically significant higher than that of DDP4 inhibitors. (OR=2.85, 95%CI :1.71-4.76, P < 0.01). Conclusion Empagliflozin can effectively reduce the fasting blood glucose,HbAIc, and body weight, but increase the incidence of genital infection compare with DDP4 inhibitors. |
| keywords:Empagliflozin DDP4 inhibitors Type 2 diabetes Meta-analysis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
